Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium.
Devos T, Verhoef G, Steel E, Mazure D, Lewalle P, Bron D, Berneman Z, Benghiat FS, Mineur P, Theunissen K, Zachée P, Doyen C, Put N, Lejeune M, Van Eygen K, Havelange V, Reusens M, Pluymers W, Peeters K. Devos T, et al. Among authors: van eygen k. Acta Haematol. 2019;142(4):197-207. doi: 10.1159/000499329. Epub 2019 Jun 4. Acta Haematol. 2019. PMID: 31163431 Free article. Clinical Trial.
Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
Devos T, Havelange V, Theunissen K, Meers S, Benghiat FS, Gadisseur A, Vanstraelen G, Vellemans H, Bailly B, Granacher N, Lewalle P, De Becker A, Van Eygen K, Janssen M, Triffet A, Vrelust I, Deeren D, Mazure D, Bekaert J, Beck M, Selleslag D. Devos T, et al. Among authors: van eygen k. Ann Hematol. 2021 Jul;100(7):1723-1732. doi: 10.1007/s00277-021-04507-x. Epub 2021 May 4. Ann Hematol. 2021. PMID: 33942128 Free PMC article.
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study.
Noens L, van Lierde MA, De Bock R, Verhoef G, Zachée P, Berneman Z, Martiat P, Mineur P, Van Eygen K, MacDonald K, De Geest S, Albrecht T, Abraham I. Noens L, et al. Among authors: van lierde ma, van eygen k. Blood. 2009 May 28;113(22):5401-11. doi: 10.1182/blood-2008-12-196543. Epub 2009 Apr 6. Blood. 2009. PMID: 19349618 Free article.
Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes.
Delforge M, Selleslag D, Beguin Y, Triffet A, Mineur P, Theunissen K, Graux C, Trullemans F, Boulet D, Van Eygen K, Noens L, Van Steenweghen S, Lemmens J, Pierre P, D'hondt R, Ferrant A, Deeren D, Van De Velde A, Wynendaele W, André M, De Bock R, Efira A, Breems D, Deweweire A, Geldhof K, Pluymers W, Harrington A, MacDonald K, Abraham I, Ravoet C. Delforge M, et al. Among authors: van de velde a, van eygen k, van steenweghen s. Leuk Res. 2014 May;38(5):557-63. doi: 10.1016/j.leukres.2014.02.003. Epub 2014 Feb 14. Leuk Res. 2014. PMID: 24661630
Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis.
Kastritis E, Palladini G, Minnema MC, Wechalekar AD, Jaccard A, Lee HC, Sanchorawala V, Gibbs S, Mollee P, Venner CP, Lu J, Schönland S, Gatt ME, Suzuki K, Kim K, Cibeira MT, Beksac M, Libby E, Valent J, Hungria V, Wong SW, Rosenzweig M, Bumma N, Huart A, Dimopoulos MA, Bhutani D, Waxman AJ, Goodman SA, Zonder JA, Lam S, Song K, Hansen T, Manier S, Roeloffzen W, Jamroziak K, Kwok F, Shimazaki C, Kim JS, Crusoe E, Ahmadi T, Tran N, Qin X, Vasey SY, Tromp B, Schecter JM, Weiss BM, Zhuang SH, Vermeulen J, Merlini G, Comenzo RL; ANDROMEDA Trial Investigators. Kastritis E, et al. N Engl J Med. 2021 Jul 1;385(1):46-58. doi: 10.1056/NEJMoa2028631. N Engl J Med. 2021. PMID: 34192431 Clinical Trial.
Obinutuzumab plus Lenalidomide (GALEN) for the treatment of relapse/refractory aggressive lymphoma: a phase II LYSA study.
Houot R, Cartron G, Bijou F, de Guibert S, Salles GA, Fruchart C, Bouabdallah K, Maerevoet M, Feugier P, Le Gouill S, Tilly H, Casasnovas RO, Moluçon-Chabrot C, Van Den Neste E, Zachee P, Andre M, Bonnet C, Haioun C, Van Hoof A, Van Eygen K, Molina L, Nicolas-Virelizier E, Ruminy P, Morschhauser F. Houot R, et al. Among authors: van hoof a, van eygen k, van den neste e. Leukemia. 2019 Mar;33(3):776-780. doi: 10.1038/s41375-018-0282-y. Epub 2018 Oct 5. Leukemia. 2019. PMID: 30291335 Free article. Clinical Trial. No abstract available.
Results from the Belgian mantle cell lymphoma registry.
Vergote V, Janssens A, André M, Bonnet C, Van Hende V, Van Den Neste E, Van Eygen K, Maerevoet M, Pranger D, Schroyens W, Debussche S, Maertens V, Beel K, Lemmens J, Caron C, Delrieu V, Van Den Broeck I, Vanstraelen G, Jacquy C, Schauvlieghe L, De Samblanx H, Madoe V, Meers S, Boulet D, Verhoef G, Van Hoof A. Vergote V, et al. Among authors: van hende v, van hoof a, van eygen k, van den neste e, van den broeck i. Acta Clin Belg. 2017 Jun;72(3):172-178. doi: 10.1080/17843286.2017.1293328. Epub 2017 Feb 22. Acta Clin Belg. 2017. PMID: 28222652 Free article.
Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
Morschhauser F, Le Gouill S, Feugier P, Bailly S, Nicolas-Virelizier E, Bijou F, Salles GA, Tilly H, Fruchart C, Van Eygen K, Snauwaert S, Bonnet C, Haioun C, Thieblemont C, Bouabdallah R, Wu KL, Canioni D, Meignin V, Cartron G, Houot R. Morschhauser F, et al. Among authors: van eygen k. Lancet Haematol. 2019 Aug;6(8):e429-e437. doi: 10.1016/S2352-3026(19)30089-4. Epub 2019 Jul 8. Lancet Haematol. 2019. PMID: 31296423 Free article. Clinical Trial.
52 results